Emergent BioSolutions EBS
NYSE EBS
$6.22 +0.02 (+0.32%)
As of: Oct 22, 2026 · 3:59 PM EDT

Emergent BioSolutions (EBS) Liabilities from Discontinued Operations (2015 - 2025)

Updated

Emergent BioSolutions (EBS) reported Liabilities from Discontinued Operations of $4.5 million for Q3 2025, down 4.3% from the prior quarter.

Analysis

Emergent BioSolutions (EBS) Liabilities from Discontinued Operations (2015 - 2025) Analysis & Trends

At the end of FY2015, Emergent BioSolutions posted Liabilities from Discontinued Operations of $3.23 million.

  • The Q3 2025 figure ranks as the lowest quarterly Liabilities from Discontinued Operations since Q4 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Emergent BioSolutions 319.92 Mn -430.98 Mn 137.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 4.50 Mn
Jun 30, 2025 4.70 Mn
Mar 31, 2025 4.80 Mn
Jun 30, 2024 10.10 Mn
Dec 31, 2015 3.23 Mn
API Access

Emergent BioSolutions Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=EBS&period=max&api_key=YOUR_API_KEY